Obesity Clinical Trials in Dallas, Texas

21 studies are recruiting for obesity in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

    Obesity is a condition where a person has excessive body fat, defined by a body mass index (BMI) of 30 kg/m2 or higher. The goal of this study is to evaluate the effect of various doses of ABBV-295 compared to placebo on reducing body weight at Week 32 in participants with obesity or overweight wit…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Velocity Clinical Research - Dallas /ID# 282734, Dallas, Texas
    Locations
    45 in total
    Run by
    AbbVie
  2. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Cedar Health Research, LLC, Dallas, Texas
    Locations
    657 in total
    Run by
    Amgen
  3. Spinal Cord Injury Model Systems (SCIMS) - Education Module

    The purpose of this study is to find out if receiving education regarding increased risks of cardiometabolic disease helps subjects understand these risks and how these risks participants' health.

    Stage
    Not phased
    Ages
    18 to 70
    Site
    Baylor Scott & White Institute for Research, Dallas, Texas
    Locations
    3 in total
    Run by
    University of Miami
  4. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    The purpose of this study is to see how oral semaglutide, when taken in lower doses help lowering of body weight in participants with excess body weight when compared to 'dummy' tablets (placebo). Results from this study will help select the most optimal lower dose of oral semaglutide that can be u…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Cedar Health Research, Dallas, Texas
    Locations
    62 in total
    Run by
    Novo Nordisk A/S
  5. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    56 in total
    Run by
    Eli Lilly and Company
  6. A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

    The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    Mercy Family Clinic, Dallas, Texas
    Locations
    42 in total
    Run by
    Eli Lilly and Company
  7. A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    157 in total
    Run by
    Eli Lilly and Company
  8. A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

    The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Locations
    187 in total
    Run by
    Eli Lilly and Company
  9. AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and type 2 diabetes. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the trea…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    UT Southwestern Med Center, Dallas, Texas
    Locations
    74 in total
    Run by
    Novo Nordisk A/S
  10. Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)

    The purpose of this study is to understand how the nervous system communicates to blood vessels to increase blood pressure during stress. The study will also investigate how hypertension and obesity influence the nervous system and vascular function. The study will involve measuring sympathetic ner…

    Stage
    EARLY_Phase 1
    Ages
    18 to 55
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  11. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

    The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

    Stage
    Phase 3
    Ages
    45 to 99
    Site
    Thyroid Endocrinology and Diabetes, Dallas, Texas
    Locations
    783 in total
    Run by
    Amgen
  12. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

    The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

    Stage
    Phase 3
    Ages
    18 to 99
    Site
    Cedar Health Research, LLC, Dallas, Texas
    Locations
    87 in total
    Run by
    Amgen
  13. Effects of Obesity in the Aged

    The overall objective of this application is to investigate the effects of obesity on lung function, exercise tolerance, and DOE in older obese adults as compared with older adults without obesity, using a novel probe for mechanically unloading the thorax at rest and during exercise. The investigat…

    Stage
    Not phased
    Ages
    65 to 75
    Site
    Institute for Exercise and Environmental Medicine, UT Southwestern and Texas Health Resources, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  14. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

    This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clin Res, Dallas, Dallas, Texas
    Locations
    303 in total
    Run by
    Novo Nordisk A/S
  15. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

    The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clinical Research, Dallas, Dallas, Texas
    Locations
    162 in total
    Run by
    Eli Lilly and Company
  16. Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

    This study is for older children, adolescents, and young adults with B-cell Acute Lymphoblastic Leukemia (B-ALL). Higher amounts of body fat is associated with resistance to chemotherapy in patients with B-ALL. Chemotherapy during the first month causes large gains in body fat in most people, even …

    Stage
    Phase 2
    Ages
    7 to 25
    Site
    University of Texas, Southwestern, Dallas, Texas
    Locations
    16 in total
    Run by
    Etan Orgel
  17. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Renal Disease Research Institute, Dallas, Texas
    Locations
    838 in total
    Run by
    Novo Nordisk A/S
  18. AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

    This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to placebo. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111, (the tr…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Mercy Family Clinic, Dallas, Texas
    Locations
    81 in total
    Run by
    Novo Nordisk A/S
  19. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

    Stage
    Phase 2
    Ages
    18 to 75
    Site
    FutureSearch Trials of Dallas, Dallas, Texas
    Locations
    40 in total
    Run by
    Eli Lilly and Company
  20. AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

    The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Velocity Clinical Res-Dallas, Dallas, Texas
    Locations
    72 in total
    Run by
    Novo Nordisk A/S
  21. Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF

    The overall purpose of this study is to investigate whether pulmonary limitations that increase the oxygen (O2) cost of breathing impact dyspnea on exertion (DOE) and peak exercise capacity in patients with HFpEF and obesity. As per investigator's hypothesis, obesity is likely a significant contrib…

    Stage
    Not phased
    Ages
    55 to 90
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.